CME Activity: Reducing CVD Risk in the Patient with High Triglycerides and Metabolic Syndrome or DM2
This online activity is based on Reducing CVD Risk in the Patient with High Triglycerides and Metabolic Syndrome or DM-2: You Be the JudgeTM held on June 1, 2012 in Scottsdale, AZ.
Selected faculty presentations (audio and slides) include
- What Is the Relationship of Hypertriglyceridemia and Low HDL-C to the Increased CVD Risk in Metabolic Syndrome and DM-2?
- What Tests Should We Order to Define CVD Risk in the HTG + MetS/DM-2 Patient?
- What Is the Best Current Lipid Management in the HTG + MetS/DM-2 Patient?
- What Agents Are in Development for Management of HTG?
This activity is designed for cardiologists, internists, lipidologists, and other healthcare professionals involved in the treatment of patients at risk of cardiac events.
Harold E. Bays, MD
Medical Director and President
Louisville Metabolic and Atherosclerosis Research Center Inc.
Eliot A. Brinton, MD
Vice President, American Board of Clinical Lipidology
President, Utah Atherosclerosis Society
President, Utah Lipid Center
Director of Atherometabolic Research
Utah Foundation for Biomedical Research
Salt Lake City, UT
W. Virgil Brown, MD
Professor Emeritus, Medicine
Emory University School of Medicine
Terry A. Jacobson, MD
Professor of Medicine
Director, Office of Health Promotion and Disease Prevention
Co-Director, Lipid and Cardiovascular Risk Reduction Program
Grady Health Systems